Infect Immun 2008, 76:1239–1246.PubMedCrossRef 65. Weening EH, Parveen N, Trzeciakowski JP, Leong JM, Hook M, Skare JT: Borrelia burgdorferi lacking DbpBA exhibits an early survival defect during experimental infection. Infect Immun 2008,76(12):5694–5705.PubMedCrossRef 66. Ouyang Z, Haq S, Norgard MV: Analysis of the dbpBA upstream regulatory region controlled by RpoS in Borrelia burgdorferi . J Bacteriol 2010,192(7):1965–1974.PubMedCrossRef 67. Becker G, Hengge-Aronis R: What makes an Escherichia coli

https://www.selleckchem.com/products/bb-94.html promoter sigma(S) dependent? Role of the -13/-14 nucleotide promoter positions and region 2.5 of sigma(S). Mol Microbiol 2001,39(5):1153–1165.PubMedCrossRef 68. Typas A, Becker G, Hengge R: The molecular basis of selective promoter activation by the sigmaS EPZ015666 concentration subunit of RNA polymerase. Mol Microbiol 2007,63(5):1296–1306.PubMedCrossRef 69. Narasimhan S, Caimano MJ, Liang FT, Santiago F, Laskowski M, Philipp MT, Pachner AR, Radolf JD, Fikrig E: Borrelia burgdorferi

transcriptome in the central nervous system of non-human primates. Proc Natl Acad Sci USA 2003,100(26):15953–15958.PubMedCrossRef 70. Pal U, Wang P, Bao F, Yang X, Samanta S, Schoen R, Wormser GP, Schwartz I, Fikrig E: Borrelia burgdorferi basic membrane proteins A and B participate in the genesis of Lyme arthritis. J Exp Med 2008,205(1):133–141.PubMedCrossRef 71. Pollack RJ, Telford SR, Spielman A: selleck products Standardization of medium for culturing Lyme disease spirochetes. J Clin Microbiol 1993,31(5):1251–1255.PubMed 72. Yang X, Coleman AS, before Anguita J, Pal U: A chromosomally encoded virulence factor protects the Lyme disease pathogen against host-adaptive immunity. PLoS Pathog 2009,5(3):e1000326.PubMedCrossRef Authors’ contributions ZO, SN, GN, and MK performed experiments. ZO and

MVN analyzed results. ZO, UP, EF and MVN participated in experimental designs and writing of the manuscript. All authors read and approved the manuscript.”
“Background Antibiotic-resistant Staphylococcus aureus strains emerging from the community as well as hospital environments represent a global threat [1, 2], requiring new approaches to control this pathogen. The anterior nare is the major reservoir of S. aureus in humans; 80% of the human population may be carriers [3]. A causal relationship between nasal colonization of S. aureus and serious infection has been established; thus, eliminating S. aureus nasal carriage may reduce the risk of infection [4, 5]. Coagulase-negative Staphylococci (CoNS) are known commensal flora of the skin and mucous membranes and also colonize human anterior nares. Recently CoNS have been recognised as opportunistic pathogens responsible for the increasing incidence of serious nosocomial infections, mainly because of their affinity for the foreign materials used in prosthetics and indwelling devices.